Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F16%3A00011300" target="_blank" >RIV/00023736:_____/16:00011300 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/16:00089657 RIV/00216208:11110/16:10314163 RIV/00216208:11130/16:10314163 RIV/00216208:11150/16:10314163 and 3 more
Result on the web
<a href="http://dx.doi.org/10.1111/ejh.12554" target="_blank" >http://dx.doi.org/10.1111/ejh.12554</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ejh.12554" target="_blank" >10.1111/ejh.12554</a>

Result language
angličtina
Original language name
Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide
Original language description
In our cohort of 1179 patients with MPD-T, prospectively registered for anagrelide treatment, we found that the median platelet count prior to the thrombotic event was significantly higher than at time points without any ensuing thrombosis (453 vs. 400 109 /l, P<0.001), albeit higher platelet counts at diagnosis tended to be connected with fewer thrombotic events (in contrast to WBC counts at diagnosis). Our results suggest that keeping platelet counts at low levels may be a meaningful therapeutic measure to prevent thrombosis, although their counts at diagnosis lack any prognostic value.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)